A novel hirudin derivative characterized with anti-platelet aggregations and thrombin inhibition

Journal of Thrombosis and Thrombolysis

Volumn 28, Issue 2, 2009, Pages 230-237

  Mo, Wei ^a   Zhang, Yan Ling ^a   Chen, Hong Shan ^a   Wang, Long Sheng ^a   Song, Hou Yan ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Anti thrombotic therapy; Carotid artery anastomosis; Novel anti coagulant; Recombinant r RGD hirudin

Indexed keywords

ABCIXIMAB; ADENOSINE DIPHOSPHATE; HIRUDIN; HIRUDIN DERIVATIVE; RECOMBINANT ARGINYLGLYCYLASPARTIC ACID HIRUDIN; THROMBIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTERY ANASTOMOSIS; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; DRUG MECHANISM; HISTOPATHOLOGY; LOW DRUG DOSE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PHARMACODYNAMICS; PICHIA PASTORIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTHROMBIN TIME; RABBIT; THROMBIN TIME; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; WILD TYPE;

ANIMALS; ANTICOAGULANTS; BLEEDING TIME; HIRUDINS; MALE; PICHIA; PLASMIDS; PLATELET AGGREGATION; PROTEIN ENGINEERING; RABBITS; RECOMBINANT PROTEINS; THROMBIN;

EID: 67849111443     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-008-0251-9     Document Type: Article

References (14)

1. Markwardt F, Sturzebecker J, Griessbach U (1970) Hirudin as an inhibitor of thrombin. Meth Enzymol 19:924-932
2. Chang JY (1983) The functional domain of hirudin, a thrombin-specific inhibitor. FEBS Lett 164:307-313
3. Modi NB, Baughman SA, Paasch BD et al (1995) Pharmacokinetics and pharmacodynamics of TP-9201, a GP IIb/IIIa antagonist, in rats and dogs. J Cardiovasc Pharmacol 25:888-897
4. Adelman B, Gennings C, Strony J et al (1990) Synergistic inhibition of platelet aggregation by fibrinogen-related peptides. Cirs Res 67:941-947
5. Marsh Lyle E, Lewis SD, Lehman ED et al (1998) Assessment of thrombin inhibitor efficacy in a novel rabbit model of simultaneous arterial and venous thrombosis. Thromb Haemost 79(3):656-662
6. Leadley RJ, Kasiewski CJ, Bostwick JS et al (1997) Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rt-PA in the stenosed canine coronary artery. Thromb Haemost 78(4):1278-1285
7. Coller Barry S (2001) Anti-GP IIb/IIIa drugs: Current strategies and future directions. Thromb Haemost 86:427-443
8. Narayanan K, Walenga JM et al (1991) Recombinant hirudin-initial observation in reconstructive microsurgery. Haemostasis 21(suppl 1):168-171
9. White CM (2005) Thrombin-directed inhibitors: Pharmacology and clinical use. Am Heart J 149(Suppl 1):S54-S60
10. Lehman ED, Joyce JF, Bailey J et al (1993) Expression, purification and characterization of multigram amounts of a recombinant hybrid HV1-HV2 hirudin variant expressed in Saccharomyces cerevisiae. Protein Expr Purif 4:247-255
11. Warkentin TE, Powling MJ, Hardisty RM (1990) Measurement of fibrinogen binding to platelets in whole blood by flow cytometry. Br J Haematol 76:387-394
12. Roesken F, Vollmar B, Rucker M et al (1998) In vivo analysis of antithrombotic effectiveness of recombinant hirudin on microvascular thrombus formation and recanalization. J Vasc Surg 28(3):498-505
13. Zokai K, Piazolo L, Harenberg J et al (2001) Effect of thrombin inhibitors and a glycoprotein IIb/IIIa receptor antagonist in an ex vivo human experimental thrombosis model. Semin Thromb Hemost 27(5):531-536
14. Lavelle SM, MacIomhair M et al (1998) Bleeding times and the antithrombotic effects of high-dose aspirin, hirudin and heparins in the rat. J Ment Sci 167(4):216-220